Compounded GLP-1 drugs aren't FDA-approved and may carry unknown safety risks. Experts warn of inconsistent quality, dosing and possible side effects in compounded meds. Lifestyle habits—like diet, ...

Telehealth Provider Offers FDA-Approved and Compounded Weight Loss Medications in All 50 States, Subject to RegulationsSAN DIEGO, Dec. 26, 2025 (GLOBE NEWSWIRE) -- As the post-holiday period brings ...

Before you fill that prescription. Reviewed by Dietitian Maria Laura Haddad-Garcia Compounded GLP-1 drugs aren't FDA-approved and may carry unknown safety risks. Experts warn of inconsistent quality, ...

If you're following the GLP-1 (Ozempic and other prescription weight-loss medications) scene, you may have read that the FDA set a cut-off date for this month on pharmacies that compound GLP-1 ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have revolutionized the management of metabolic diseases, offering substantial benefits in glycemic control, weight reduction, cardiovascular ...

Until recently, several glucagon-like peptide-1 (GLP-1) injections were in shortage. During this time, compounded versions became a more accessible option. Now, brand-name GLP-1 injections of ...

Nearly half of seniors quit GLP-1 weight-loss drugs within a year. Experts reveal why older Americans abandon medications ...

Sprout Health Serves as Case Study for Provider Model Structure, Program Costs, and FDA-vs-Compounded Disclosure ...

The mounting conversations around compounded GLP-1 medications aren’t just about science or safety. Rather, lawsuits and corporate power plays have had massive influence on how these drugs are being ...

The supply of GLP-1 drugs for weight loss and diabetes treatment was expected to tighten this week with a federal deadline to halt the sale and production of off-brand products that many patients in ...

Discover how compounding pharmacies are transforming healthcare by creating tailor-made medications for patients with unique needs, offering critical alternatives when standard drugs fall short, and ...